PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

UK sees a 20% growth in the number of advanced therapy trials, report finds

The UK has had a 20% growth in the number of advanced therapy medicinal product (ATMP) clinical trials, according to a new report from the Cell and Gene Therapy Catapult (CGT Catapult).

The report shows there were 154 ongoing ATMP clinical trials reported in total in 2020 – a 20% increase since 2019.

The 2020 ATMP clinical trials database and report also found that the number of commercially sponsored trials has seen a surge since 2019, increasing by almost 30% from 89 to 115.

This increase includes a growth in late-stage clinical trials, highlighting a continued progression towards commercialisation, according to CGT Catapult.

“Such a remarkable rise in the number of UK clinical trials in just one year is a testament to the tremendous strength of the entire UK ATMP industry and continuous backing of the government in progressing it,” said Matthew Durdy, chief executive officer of CGT Catapult.

“The UK’s robust clinical space complements the growth seen in the GMP manufacturing space last year both contributing to a cementing of the infrastructure supporting ATMP developers in the UK,” he added.

In addition, the report shows a decrease in the number of trials closing and a number of sites have reported putting trials on hold.

“The full extent of the pandemic’s impact may not yet be fully ascertained and may result in a slight slowing of growth in the coming years,” CGT Catapult said in a statement.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026